Morgan Stanley (MS) Falls 4.35% for January 18

Equities Staff |

One of the S&P 500’s big losers for Monday January 18 was Morgan Stanley (MS). The company’s stock fell 4.35% to $25.97 on volume of 29.46 million shares.

The stock opened the day at 26.03 and traded between a low of $25.51 and a high of $26.41. The stock finished the day down $1.18 per share. Morgan Stanley has an average daily volume of 13.06 million and a total float of 1.94 billion shares. The 50-day SMA for Morgan Stanley is $32.60 and its 200-day SMA is $35.33. The high for the stock over the last 52 weeks is $41.04 and the low is $25.51.

Morgan Stanley through its subsidiaries and affiliates, provides financial products and services to a diversified group of clients and customers, including corporations, governments, financial institutions and individuals.

Morgan Stanley is centered in New York, NY, and has 56,267 employees. Today’s trading day leaves the company with a market cap of $50.28 billionwith a P/E Ratio of 8.7. The company has a P/S ratio of 1.77, P/B ratio of 0.74, and a -5.

For a complete fundamental analysis analysis of Morgan Stanley, check out’s Stock Valuation Analysis report for MS. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.